RNXT Stock Forecast: RenovoRx, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.96
−8.72% on the day

The median 12-month analyst price target for RenovoRx, Inc. is $5.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 34 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$46.2M
Ticker Nerd rank
34/ 100
Median analyst target
$5.50
Analysts covering
4
Revenue$909K+115.4% y/y
Operating income−$3.3M
Net income−$2.9M
Free cash flow−$2.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.8%
1M
−20.1%
YTD
+14.1%
1Y
+23.2%
From 52W high
−62.0%
From 52W low
+23.2%
$0.78
$2.52
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores RenovoRx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
34/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
58
Momentum
52
Growth
50
Accruals
45
Volatility
45
Quality
28
Value
23
Issuance
18

Revisions (58): Analysts have, on balance, been raising their forecasts.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RNXT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNXT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26RNXTHigh $15.00Median $5.50Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$3.00
Low
$5.50
Median
$15.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Nov 2026Ascendiant CapitalMaintainsBuy$15 → $15
28 Aug 2026Ascendiant CapitalMaintainsBuy$14 → $15
1 June 2026Ascendiant CapitalMaintainsBuy$14 → $14
9 Apr 2026Ascendiant CapitalMaintainsBuy—
8 Apr 2026HC Wainwright & Co.ReiteratesBuy—
17 Feb 2026Ascendiant CapitalMaintainsBuy—
21 Nov 2025Ascendiant CapitalMaintainsBuy—
25 Aug 2025Ascendiant CapitalMaintainsBuy—
5 June 2025Ascendiant CapitalMaintainsBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Apr 2025Ascendiant CapitalMaintainsBuy—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
27 Mar 2025HC Wainwright & Co.InitiatesBuy—
10 Dec 2024Ascendiant CapitalMaintainsBuy—
12 Sept 2024Ascendiant CapitalMaintainsBuy—
17 June 2024Ascendiant CapitalInitiatesBuy—
2 Feb 2024Alliance Global PartnersInitiatesBuy—
15 Nov 2023Maxim GroupDowngradeHold—
18 Aug 2023Roth MKMMaintainsBuy—
1 Nov 2021Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RNXT.

Market Radar

This page is one stock. Monday covers all of them.

RNXT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RNXT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, RenovoRx, Inc. returned +23.2% against +6.9% for the S&P 500, dividends included.

RNXT vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26RNXTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RNXT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
16.4×

Cheaper than 9% of US stocks

Price / book
4.9×

Cheaper than 19% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
84.3%

Higher than 93% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−150.0%

Higher than 10% of US stocks

Return on assets
−68.6%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • RenovoRx, Inc. has a market value of $46.2M and an enterprise value of $35.4M.

  • Revenue in the twelve months to 30 June 2026: $2.0M. The latest quarter grew 115.4% year on year.

  • Net income over the same four quarters: −$12.3M, a −621.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$11.9M.

  • Shares outstanding: 45.1M.

  • RenovoRx, Inc. employs 17 people — $116K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

RNXT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNXTRenovoRx, Inc.$46.2M34
APLMApollomics, Inc.$45.3M9
HOWLWerewolf Therapeutics, Inc.$46.0M90
MISTMilestone Pharmaceuticals, Inc.$46.2M29
TNXPTonix Pharmaceuticals Holding Corp.$46.2M22
GANXGain Therapeutics, Inc.$44.5M32
ANVSAnnovis Bio, Inc.$44.1M16

Take a look at RNXT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own RenovoRx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RNXT

What is the RNXT stock price forecast for 2026-2027?

The median 12-month analyst price target for RenovoRx, Inc. is $5.5, with estimates ranging from $3 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RNXT stock a buy right now?

Of the 4 analysts covering RenovoRx, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks RenovoRx, Inc. 34 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNXT?

As at 21 Nov 2026, RenovoRx, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (58 of 100).

Will RNXT stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $5.5, and Ticker Nerd's factor model ranks RenovoRx, Inc. 34 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RNXT stock forecast for 2030?

No analyst covering RenovoRx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNXT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $15 over the next 12 months.

How has RNXT stock performed over the past year?

RenovoRx, Inc. returned +23.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does RenovoRx, Inc. do?

RenovoRx, Inc. is a life sciences company focused on targeted oncology therapies and localized drug delivery for cancer treatment. Its core offering includes RenovoCath, an FDA-cleared local drug delivery device designed to deliver chemotherapy directly to tumor sites while limiting exposure to healthy tissue.

Company

About RenovoRx, Inc.

RenovoRx, Inc. is a life sciences company focused on targeted oncology therapies and localized drug delivery for cancer treatment. Its core offering includes RenovoCath, an FDA-cleared local drug delivery device designed to deliver chemotherapy directly to tumor sites while limiting exposure to healthy tissue. The company also develops its Trans-Arterial Micro-Perfusion therapy platform, which is intended for precise intra-arterial delivery of cancer treatments in solid tumors. RenovoRx’s work centers on addressing high unmet medical needs in oncology, with particular emphasis on improving how therapies are administered in clinical settings. The company operates at the intersection of medical technology and biopharmaceutical development, serving the broader cancer care market through device-enabled drug delivery solutions.

CEO Mr. Shaun R. Bagai · 17 employees · United States · https://renovorx.com